Ensysce Biosciences Reports Second Quarter 2024 Financial Results

August 14, 2024 4:15 PM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the second quarter ended June 30, 2024.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our FDA-designated Breakthrough Therapy product candidate,...

Read more

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)

August 14, 2024 9:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today provided an update on the U.S. Food and Drug Administration (FDA) premarket approval (PMA) application status for its lead product, a surgical replacement venous valve called the VenoValve. Four (4) out of five (5) modules that comprise the VenoValve PMA application have now been submitted,...

Read more

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

August 14, 2024 8:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2024. "We remain confident in the potential of our DNase-based oncology platform and continue to advance our preclinical studies with data expected before year end. Looking ahead, we are...

Read more

dermaFIT Muscle Cream: The World’s First and Only Muscle Retention Cream Now Available at dermaFIT.com

August 13, 2024 9:00 AM

FULLERTON, CA / ACCESSWIRE / August 13, 2024 / EX Healthcare, a leading skin healthcare company, is proud to announce the launch of dermaFIT, the world's first and only muscle retention cream, now available for purchase at dermaFIT.com.dermaFIT Muscle Retention Cream dermaFIT's three types of muscel retention cream: Strength for daily protection, Extra-Strength for double support and Sculpt for slimming. Developed by EX Healthcare, dermaFIT is a...

Read more

Lifeloc Reports Second Quarter 2024 Results

August 8, 2024 4:18 PM

WHEAT RIDGE, CO / ACCESSWIRE / August 8, 2024 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2024.Second Quarter Financial HighlightsLifeloc posted quarterly net revenue of $2.387 million in the second quarter of 2024, resulting in a quarterly net loss of $(298) thousand, or $(0.12) per...

Read more

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

August 8, 2024 8:25 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides a summary of its successful symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium illustrated the current landscape of...

Read more

Scorpius Holdings, Inc. Announces Pricing of Public Offering

August 6, 2024 9:25 PM

DURHAM, NC / ACCESSWIRE / August 6, 2024 / Scorpius Holdings, Inc. (NYSE American:SCPX), ("Scorpius", or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of an underwritten public offering of 12,500,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being offered at a public offering...

Read more

International Perinatal Stem Cell Society Calls for Updated U.S. Regulatory Framework for Stem Cell and Tissue Products

August 6, 2024 5:50 PM

The International Perinatal Stem Cell Society has released a position paper advocating for changes to the U.S. regulatory landscape for perinatal stem cell and tissue products. The Society argues that while FDA guidance has driven innovation in the past, the current regulatory framework is now holding back advancements in regenerative medicine. The Society believes that these changes will help restore the U.S. as a global leader in regenerative...

Read more

Vibrant Wellness Improves Turnaround Times for Key Lab Tests

August 6, 2024 9:30 AM

SANTA CLARA, CA / ACCESSWIRE / August 6, 2024 / Vibrant Wellness, a leading CLIA-certified and CAP-accredited lab, is excited to announce significant reductions in turnaround times for several of its core lab tests. This milestone underscores Vibrant's commitment to improving healthspan and longevity by enabling earlier, targeted detection of challenging health conditions.Rapid Turnaround Times for Earlier InterventionsWhile many competitors...

Read more

BioLumic Pioneers New Seed Traits with Seed Company Partners

August 6, 2024 9:00 AM

BioLumic, the world's only company treating seeds with light to activate genetic expression for new crop traits, has achieved a breakthrough in enhancing inbred corn lines. These genetically 'pure' parent seeds are crucial for producing the world's high-performing hybrid seeds favored by most farmers.After achieving significant performance milestones in 2023 field trials, BioLumic is partnering with Beck's Hybrids, Peterson Corn Genetics,...

Read more

Scorpius Holdings Weighted-Average Pipeline Surpasses $100 Million in Business Develop Opportunities Across Both Manufacturing Client and Government Sectors

August 6, 2024 8:45 AM

Scorpius Holdings, Inc (NYSE American:SCPX), ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced that it has surpassed $100 million in weighted average pipeline of its near-term business development opportunities across both government and manufacturing client sectors. The weighted average pipeline is represented by written proposals which are subject to the execution of...

Read more

OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

August 6, 2024 8:35 AM

ROCKVILLE, MD / ACCESSWIRE / August 6, 2024 / OS Therapies (NYSE American:OSTX) ("OS Therapies" or "the Company"), an Antibody Drug Conjugate (ADC) and Immunotherapy research and clinical-stage biopharmaceutical company, highlights its Scientific and Medical Advisory Board (SMAB), comprised of experts in osteosarcoma from six institutions in the United States.The following physicians have agreed to serve on the OS Therapies SMAB:• Nabil M....

Read more

Ondine Biomedical Inc. Announces Leeds Teaching Hospital NHS Trust to use Steriwave

August 6, 2024 2:00 AM

Leeds Teaching Hospitals NHS Trust to use SteriwaveVANCOUVER, BC / ACCESSWIRE / August 6, 2024 / Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, and Iskus Health announce that Leeds Teaching Hospitals NHS Trust will begin using its Steriwave® nasal decolonization technology later this month. Leeds Teaching Hospitals NHS Trust is one of the largest and busiest acute...

Read more

Med-X Poised for Global Expansion and NASDAQ Listing Amidst 200% Revenue Growth

August 5, 2024 9:45 AM

Med-X, the parent company of Nature-Cide, Malibu Brands, and Thermal-Aid - leading natural pesticide and pain-management brands, respectively - is planning a NASDAQ listing in the near future. But they're offering private investors an opportunity to join them before it happens.More than just a pest control and health & wellness product developer, Med-X has an entire portfolio of green products aiming to supply natural solutions that reduce...

Read more

enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 1, 2024 8:05 AM

- Ended the quarter with $39.1 million cash and investments on hand sufficient to fund operations, through the end of 2025, including potential PMA approval of VenoValve®- Positive interim venous ulcer healing data showing significant improvement from the VenoValve pivotal trial presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting- Company on track to file application seeking VenoValve FDA approval in Q4 2024- Continued...

Read more

Indica Labs Announces Launch of AI-Powered Macrodissection Suite to Advance Molecular Pathology Workflows

August 1, 2024 8:00 AM

Indica Labs, the leading provider of AI-powered digital pathology solutions, proudly announces the launch of Lung Macrodissect AI, a groundbreaking tool that revolutionizes sli­­de macrodissection and molecular pathology workflows. Lung Macrodissect AI represents a significant leap forward for the integration of artificial intelligence with digital pathology by offering pathologists a streamlined macrodissection workflow that minimizes human...

Read more

Vista BioMedical(TM), Inc. Introduces VPAATH(C), an AI-Based Program that Identifies Individual High Risk, High Utilizing Patients Using Social Determinants of Health Factors

July 30, 2024 3:00 PM

ROCHESTER, MN / ACCESSWIRE / July 30, 2024 / Vista BioMedical™, Inc., a medical device and software development company, has launched VPAATH©, a pro-active, predictive AI-based program that can identify individual high risk, high utilizing patients, down to the zip code. VPAATH uses AI analysis for pinpointed SDOH (Social Determinants of Health) factors coupled with individual health risk factors to formulate an overall personalized health...

Read more

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

July 30, 2024 9:00 AM

Allowed US patent application for anti-TNFR2 antibody BI-1910 covers composition-of-matter protection and the use of antibody to treat cancerPatent will further strengthen IP protection of BioInvent's innovative portfolio of clinical assetsBI-1910 is being studied in a Phase 1/2a trial as both a single agent and in combination with KEYTRUDA® for the treatment of solid tumorsLUND, SWEDEN / ACCESSWIRE / July 30, 2024 / BioInvent International AB...

Read more

Adolore BioTherapeutics Announces Publication of Compelling Preclinical Efficacy and Safety Data Supporting Adolore's Non-opioid Analgesic Gene Therapy, ADLR-1001, For Treatment of Moderate to Severe Chronic Knee Pain Due to Osteoarthritis (OA)

July 30, 2024 8:10 AM

Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced the publication of its manuscript entitled, "Disease-Modifying rdHSV-CA8* Non-Opioid Analgesic Gene Therapy Treats Chronic Osteoarthritis Pain by Activating Kv7 Voltage-Gated Potassium Channels[1], " in the peer-reviewed journal, Frontiers in Molecular...

Read more

AmplifyBio Partners with Industry Leader in Lipid Nanoparticles (LNPs) to Expand Drug Delivery Capabilities

July 30, 2024 7:00 AM

WEST JEFFERSON, OH / ACCESSWIRE / July 30, 2024 / AmplifyBio, an emerging leader among mRNA discovery, development, and manufacturing service providers, announced today that it has formalized a partnership with Stephen Burgess, Ph.D. (AvaBurg LLC), to provide expertise in LNP formulations to ensure efficient encapsulation, protection, and delivery of mRNA to cells. Dr. Burgess formerly served as Chief Scientific Officer at Avanti Polar Lipids....

Read more